Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal." title="" class="btn" data-container="body" data-html="true" data-id="206909" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="Poolbeg Pharma plc"> 3,054
Activities
Technologies
Entity types
Location
Floor 24, 40 Bank St, London E14 5NR, UK
London
United Kingdom
Employees
Scale: 11-50
Estimated: 15
Engaged corporates
7Added in Motherbase
1 year, 8 months agoFocused on the development & commercialisation of innovative medicines.
Ticker: POLB
Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues.
Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Poolbeg Pharma is focussed on acquiring, developing & commercialising innovative medicines targeting diseases with a high unmet medical need
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() PharmaTimes Media Ltd Pharmaceutical, Pharmaceutical Manufacturing | PharmaTimes Media Ltd Pharmaceutical, Pharmaceutical Manufacturing | Other 11 Dec 2024 | | |
![]() KPMG Consulting, audit, Accounting | KPMG Consulting, audit, Accounting | Other 24 Oct 2024 | | |
![]() Dia & Co Semiconductors, Retail Apparel and Fashion | Dia & Co Semiconductors, Retail Apparel and Fashion | Other 29 Jul 2024 | | |
![]() Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 29 Jul 2024 | | |
![]() | Biotechnology Innovation Organization | Other 10 Jun 2024 | | |
![]() Financial Times Media, Newspaper Publishing | Financial Times Media, Newspaper Publishing | Other 17 Oct 2024 | | |
![]() Tiroler Tageszeitung Hospitality, Media Production | Tiroler Tageszeitung Hospitality, Media Production | Other 19 Oct 2023 | |